# Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

> **NCT02260687** · — · COMPLETED · sponsor: **Bayer** · enrollment: 353 (actual)

## Conditions studied

- Choroidal Neovascularization

## Interventions

- **DRUG:** Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT02260687
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-05
- **Primary completion:** 2018-04-02
- **Final completion:** 2018-08-22
- **Target enrollment:** 353 (ACTUAL)
- **Last updated:** 2019-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260687, "Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02260687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*